BRPI0819175A2 - Composição farmacêutica oftálmica, e, método para proporcionar disponibilidade estendida de um componente farmacêutico em um ambiente ocular de um indivíduo, e, uso de pelo menos um componente farmacêutico, pelo menos um material imiscível em água e opcionalmente um composto modificador de viscosidade - Google Patents
Composição farmacêutica oftálmica, e, método para proporcionar disponibilidade estendida de um componente farmacêutico em um ambiente ocular de um indivíduo, e, uso de pelo menos um componente farmacêutico, pelo menos um material imiscível em água e opcionalmente um composto modificador de viscosidadeInfo
- Publication number
- BRPI0819175A2 BRPI0819175A2 BRPI0819175A BRPI0819175A2 BR PI0819175 A2 BRPI0819175 A2 BR PI0819175A2 BR PI0819175 A BRPI0819175 A BR PI0819175A BR PI0819175 A2 BRPI0819175 A2 BR PI0819175A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical component
- pharmaceutical
- optionally
- individual
- water immiscible
- Prior art date
Links
- 239000005426 pharmaceutical component Substances 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000463 material Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98530807P | 2007-11-05 | 2007-11-05 | |
PCT/US2008/080665 WO2009061607A2 (en) | 2007-11-05 | 2008-10-22 | Water-immiscible materials as vehicles for drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0819175A2 true BRPI0819175A2 (pt) | 2015-05-05 |
Family
ID=40185076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0819175 BRPI0819175A2 (pt) | 2007-11-05 | 2008-10-22 | Composição farmacêutica oftálmica, e, método para proporcionar disponibilidade estendida de um componente farmacêutico em um ambiente ocular de um indivíduo, e, uso de pelo menos um componente farmacêutico, pelo menos um material imiscível em água e opcionalmente um composto modificador de viscosidade |
Country Status (13)
Country | Link |
---|---|
US (1) | US20100286121A1 (pt) |
EP (1) | EP2214644B1 (pt) |
JP (1) | JP2011502990A (pt) |
KR (1) | KR20100067684A (pt) |
CN (1) | CN101848701A (pt) |
AU (1) | AU2008325036B2 (pt) |
BR (1) | BRPI0819175A2 (pt) |
CA (1) | CA2703000C (pt) |
ES (1) | ES2402321T3 (pt) |
HK (1) | HK1144073A1 (pt) |
MX (1) | MX2010004366A (pt) |
SG (1) | SG185955A1 (pt) |
WO (1) | WO2009061607A2 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010088548A1 (en) | 2009-01-29 | 2010-08-05 | Forsight Labs, Llc | Posterior segment drug delivery |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
EP2394636B1 (en) * | 2010-05-28 | 2014-03-19 | Novagali Pharma S.A. | Method for treating retinal conditions using an intraocular tamponade |
WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
SI2600812T1 (sl) | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Naprava za zdravljenje očesa |
EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
EP4249059A3 (en) | 2011-06-28 | 2023-11-29 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
LT2755600T (lt) | 2011-09-16 | 2021-04-26 | Forsight Vision4, Inc. | Skysčio pakeitimo aparatas |
WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
EP3808339A1 (en) | 2012-05-03 | 2021-04-21 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP4008355A1 (en) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
CA2907681C (en) | 2013-03-28 | 2022-11-22 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
EP3124023B1 (en) * | 2014-03-27 | 2023-08-30 | Servicio Andaluz De Salud | Durable preparation of an injectable of melatonin exhibiting long-term stability |
KR102416726B1 (ko) | 2014-07-15 | 2022-07-05 | 포사이트 비젼4, 인크. | 안구 이식물 전달 디바이스 및 방법 |
EP3177289A4 (en) | 2014-08-08 | 2018-03-21 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
AU2015346450B2 (en) | 2014-11-10 | 2020-01-30 | Forsight Vision4, Inc. | Expandable drug delivery devices and method of use |
US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
EP3274548A4 (en) * | 2015-03-23 | 2019-01-16 | President and Fellows of Harvard College | METHODS AND COMPOSITIONS FOR INJECTING ACTIVE SOLUTIONS OF HIGH CONCENTRATION AND / OR HIGH VISCOSITY |
EP3377009B1 (en) | 2015-11-20 | 2020-10-28 | ForSight Vision4, Inc. | Porous structures for extended release drug delivery devices |
WO2017119928A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long acting injectable formulations |
EP3439591B1 (en) | 2016-04-05 | 2020-09-23 | ForSight Vision4, Inc. | Implantable ocular drug delivery devices |
LT3266446T (lt) * | 2016-07-07 | 2019-01-25 | Laboratorios Salvat, S.A. | Oftalmologinė kompozicija, apimanti ricinos aliejų ir vidutinio grandinės ilgio trigliceridą |
KR20200093581A (ko) | 2017-11-21 | 2020-08-05 | 포사이트 비젼4, 인크. | 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법 |
WO2019213326A1 (en) * | 2018-05-01 | 2019-11-07 | Idrop, Inc. | Eye drop formulation and method for sustained delivery of medicament to the retina |
CN109091675B (zh) * | 2018-08-31 | 2021-09-17 | 杭州赫尔斯科技有限公司 | 一种复方低浓度阿托品类药物滴眼液及其制备方法 |
CN113749092A (zh) * | 2020-06-03 | 2021-12-07 | 迈克斯(如东)化工有限公司 | 不饱和脂肪酸酯化物应用、农化组合物和低眼刺农药制剂及其应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3767788A (en) * | 1970-06-08 | 1973-10-23 | Burton Parsons Chemicals Inc | Ophthalmic solution |
FR2638089A1 (fr) * | 1988-10-26 | 1990-04-27 | Sandoz Sa | Nouvelles compositions ophtalmiques a base d'une cyclosporine |
JP2613139B2 (ja) * | 1990-07-19 | 1997-05-21 | エスエス製薬 株式会社 | キノロンカルボン酸誘導体 |
US5518731A (en) * | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5384333A (en) * | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
US5830508A (en) * | 1992-08-06 | 1998-11-03 | Deo Corporation | Composition for treating dry eye |
US5366739A (en) * | 1992-08-06 | 1994-11-22 | Deo Corporation | Method of ophthalmic drug delivery |
EP0656779B1 (en) * | 1992-08-28 | 2000-04-12 | Pharmos Corporation | Submicron emulsions as ocular drug delivery vehicles |
US5336487A (en) * | 1993-03-05 | 1994-08-09 | Refojo Miguel F | Method of treating eye disorders with silicon/fluorosilicone copolymer oil |
US5480914A (en) * | 1994-05-06 | 1996-01-02 | Allergan, Inc. | Nonaqueous thixotropic drug delivery suspensions and methods of their use |
US5718922A (en) * | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
CA2275525C (en) * | 1996-12-20 | 2011-02-08 | Kevin J. Brodbeck | Gel composition and methods |
CA2332271C (en) * | 1998-05-15 | 2008-08-05 | Wakamoto Pharmaceutical Co., Ltd. | Selective cyclooxygenase-2 anti-inflammatory eye drops |
US6699492B2 (en) * | 1999-03-31 | 2004-03-02 | Insite Vision Incorporated | Quinolone carboxylic acid compositions and related methods of treatment |
US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
AU2001261748A1 (en) * | 2000-05-19 | 2001-12-03 | Alcon Laboratories Inc. | Antibiotic compositions for treatment of the eye, ear and nose |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
CA2427334C (en) * | 2000-11-01 | 2013-06-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Methods and compositions for the treatment of diseases of the eye |
US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7417056B2 (en) * | 2004-11-12 | 2008-08-26 | Schering Ag | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents |
JP2008543775A (ja) * | 2005-06-08 | 2008-12-04 | ターゲジェン インコーポレーティッド | 眼の障害を治療するための方法および組成物 |
WO2008021729A2 (en) * | 2006-08-07 | 2008-02-21 | Bausch & Lomb Incorporated | Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases |
DK2056799T3 (da) * | 2006-08-31 | 2013-10-28 | Bausch & Lomb | Sammensætninger og fremgangsmåder til behandling eller forebyggelse af glaukom eller progression deraf |
JP2010502723A (ja) * | 2006-09-11 | 2010-01-28 | ボーシュ アンド ローム インコーポレイティド | アレルギーを治療、または制御、または軽減、または改善、または予防するための組成物と方法 |
JP2010529133A (ja) * | 2007-06-11 | 2010-08-26 | ボーシュ アンド ローム インコーポレイティド | フルオロキノロンを用いて炎症を調節するための組成物と方法 |
US20090082337A1 (en) * | 2007-09-21 | 2009-03-26 | Srini Venkastesh | Compositions Comprising Quinolone and Methods for Treating or Controlling Infections |
-
2008
- 2008-10-22 BR BRPI0819175 patent/BRPI0819175A2/pt not_active IP Right Cessation
- 2008-10-22 KR KR1020107009886A patent/KR20100067684A/ko not_active Application Discontinuation
- 2008-10-22 ES ES08848169T patent/ES2402321T3/es active Active
- 2008-10-22 EP EP08848169A patent/EP2214644B1/en not_active Not-in-force
- 2008-10-22 AU AU2008325036A patent/AU2008325036B2/en not_active Ceased
- 2008-10-22 CN CN200880114792A patent/CN101848701A/zh active Pending
- 2008-10-22 SG SG2012081634A patent/SG185955A1/en unknown
- 2008-10-22 WO PCT/US2008/080665 patent/WO2009061607A2/en active Application Filing
- 2008-10-22 MX MX2010004366A patent/MX2010004366A/es active IP Right Grant
- 2008-10-22 CA CA2703000A patent/CA2703000C/en not_active Expired - Fee Related
- 2008-10-22 JP JP2010532144A patent/JP2011502990A/ja active Pending
- 2008-10-22 US US12/741,266 patent/US20100286121A1/en not_active Abandoned
-
2010
- 2010-11-15 HK HK10110618.9A patent/HK1144073A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2703000C (en) | 2013-08-06 |
CN101848701A (zh) | 2010-09-29 |
AU2008325036A1 (en) | 2009-05-14 |
US20100286121A1 (en) | 2010-11-11 |
EP2214644B1 (en) | 2013-03-20 |
AU2008325036B2 (en) | 2011-10-20 |
SG185955A1 (en) | 2012-12-28 |
WO2009061607A2 (en) | 2009-05-14 |
WO2009061607A3 (en) | 2009-07-02 |
CA2703000A1 (en) | 2009-05-14 |
KR20100067684A (ko) | 2010-06-21 |
HK1144073A1 (en) | 2011-01-28 |
MX2010004366A (es) | 2010-05-05 |
JP2011502990A (ja) | 2011-01-27 |
EP2214644A2 (en) | 2010-08-11 |
ES2402321T3 (es) | 2013-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0819175A2 (pt) | Composição farmacêutica oftálmica, e, método para proporcionar disponibilidade estendida de um componente farmacêutico em um ambiente ocular de um indivíduo, e, uso de pelo menos um componente farmacêutico, pelo menos um material imiscível em água e opcionalmente um composto modificador de viscosidade | |
BRPI0719849A2 (pt) | Método de imunização contra os quatro sorotipos da dengue | |
BRPI0905663A2 (pt) | "emulsão estável, processo de preparação da emulsão estável e uso emulsão" | |
BRPI0718927A2 (pt) | Método de imunização contra os quatro sorotipos da dengue. | |
BRPI0808034A2 (pt) | Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel. | |
BRPI0810390A2 (pt) | Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero | |
CL2007002244A1 (es) | Composicion que comprende un primer componente reticulable, un segundo componente reticulable, un componente formador de un hidrogel; uso de la composicion; metodo para obturar un tracto de tejido; metodo para formar una matriz polimerica sintetica t | |
BRPI0821299A2 (pt) | Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição. | |
CR10733A (es) | Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
BRPI0908097A2 (pt) | uso de pelo menos um composto, peptídeo, e, formulação farmacêutica. | |
BRPI0907663A2 (pt) | ''composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições. | |
BRPI0807906A2 (pt) | Token pessoal tendo habilidades de comunicação aperfeiçoadas para um aplicativo hospedado. | |
BR112012012446A2 (pt) | "concentrado alimentar temperado, processo, uso, composição alimentar pronta para consumo e usp de um poliol líquido" | |
BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
BRPI0807065A2 (pt) | biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos | |
BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
BRPI0812095A2 (pt) | Composição biodegradável, método de preparação e sua aplicação na fabricação de recipientes funcionais para uso na agricultura e/ou silvicultura. | |
BRPI0816597A2 (pt) | "composto, composição farmacêutica, combinação, uso de um composto, método para tratar um indivíduo aflifido com uma consição patológica ou doença e método de modulação de uma atividade um receptor b2 adrenérgico" | |
BRPI0818459A2 (pt) | Composição farmacêutica adequada para uso oftálmico. | |
BRPI0915137A2 (pt) | uso de pelo menos um composto, peptídeo, e, formulação farmacêutica | |
BRPI0911681A2 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula | |
BRPI0719497A2 (pt) | "composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição" | |
BRPI0918487A2 (pt) | processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero | |
BRPI0607775A2 (pt) | conjugado, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de doença |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |